Comparison of Health Care Resource Utilization and Costs Among Children and Adolescents with Attention Deficit Hyperactivity Disorder in Germany Who Initiated Treatment with Atomoxetine or Long-Acting Methylphenidate

Abstract

A549ated with a lower total cost (€ 1,562) and a larger health gain (QALYs) at one year (0.732) per patient, and dominated the other treatment strategies since more QALYs were achieved at a lower total cost. Sensitivity analyses support the robustness of the model. ConClusions: The results indicate that escitalopram is the most costeffective pharmacological treatment strategy for the Italian health service compared with other SSRIs and all SNRIs used in the first-line treatment of MDD.